The place to go for the latest medical research from dozens of top academic journals

Unilateral vs. Bilateral STN-DBS: Network Impact Insights

New research reveals how unilateral and bilateral STN-DBS differently affect brain networks, shedding light on optimizing Parkinson’s treatment for better results and fewer side effects.
image-337
Was This Useful?

By CAFMI AI From npj Parkinson’s Disease (Open Access)

Distinct Motor Network Effects of Unilateral STN-DBS

Deep brain stimulation (DBS) targeting the subthalamic nucleus (STN) is a well-established treatment for advanced Parkinson’s disease (PD), typically aimed at relieving motor symptoms. This study focuses on comparing the functional brain network changes resulting from unilateral versus bilateral STN-DBS. Unilateral STN-DBS primarily enhances connectivity within motor-related brain circuits, specifically on the same side as the stimulation. Increased interaction was observed between the ipsilateral motor cortex and supplementary motor areas, which correlated positively with improvements in motor symptoms on the opposite side of the body. Clinicians can infer that unilateral stimulation offers targeted motor benefits, making it a strategic choice for patients who may not require full bilateral intervention or who might be at higher risk of side effects from more extensive stimulation.

Broader and Complex Network Changes with Bilateral STN-DBS

Bilateral STN-DBS produces a wider spectrum of functional network alterations as compared to unilateral stimulation. Beyond motor circuits, bilateral stimulation also affects prefrontal and limbic brain regions, which are associated with cognitive and emotional functions. This broader network modulation corresponds with improved control over both motor and some non-motor symptoms of PD, reflecting the therapy’s holistic benefits. However, the study noted that bilateral DBS might transiently disrupt cognitive networks, possibly explaining cognitive side effects observed in some patients. For primary care physicians, understanding these dual benefits and risks is critical for managing expectations, monitoring patients post-DBS, and coordinating with neurologists to tailor DBS strategies to individual needs.

Clinical Implications and Future Directions in STN-DBS Therapy

This research highlights the need for personalized DBS approaches based on distinct functional network outcomes. Unilateral STN-DBS could be preferred for patients focusing on unilateral motor improvements, while bilateral DBS may serve those requiring comprehensive symptom control but with careful monitoring for cognitive side effects. The findings emphasize the importance of ongoing neuroimaging to optimize DBS settings, enabling more precise targeting and minimizing adverse effects. Future investigations with larger samples and longer follow-up, using advanced imaging modalities, should refine these insights further. Ultimately, integrating functional network analysis into clinical practice could enhance therapeutic decision-making, improve patient outcomes, and advance the management of Parkinson’s disease through tailored STN-DBS interventions.


Read The Original Publication Here

(Open Access)

Was This Useful?
Clinical Insight
This study underscores the importance of personalized deep brain stimulation (DBS) strategies for Parkinson’s disease, showing that unilateral STN-DBS primarily improves motor function on one side with fewer cognitive risks, while bilateral STN-DBS offers broader symptom control including some non-motor benefits but may transiently affect cognition. For primary care physicians, these findings highlight the need to tailor patient referrals and coordinate closely with neurologists to align DBS approaches with individual clinical profiles—favoring unilateral stimulation for isolated motor symptoms or patients vulnerable to cognitive side effects, and bilateral stimulation for those needing comprehensive symptom management. Understanding the distinct functional brain network effects of each approach aids in setting realistic expectations, monitoring for potential side effects, and advocating for neuroimaging-based adjustments post-procedure. While the evidence is promising, it derives from a controlled research setting, suggesting that further large-scale studies are needed to fully validate these strategies. Nonetheless, this research equips clinicians with a nuanced framework to optimize DBS outcomes and improve quality of life for patients with advanced Parkinson’s disease.

Updated On

Published Date

Sign Up for a Weekly Summary of the Latest Academic Research
Share Now

Related Articles

image-364
Breakthroughs in Neuromodulation for Parkinson’s Care
image-363
Parkinson’s and Creativity: Surprising Patient Insights
image-362
Gut Metabolites Linked to Parkinson’s with REM Sleep Disorder
AI-assisted insights. Always verify with original research